The economic challenges faced by today’s biopharmaceutical industry are well documented. Revenues are contracting due to patent expiries, generics competition and pricing pressure from payers that are demanding clearer demonstration of product value. By 2016, patent expiries in developed markets will save payers $127 billion, primarily in the US.1 Innovative new products are scarce as R&D budgets chase increasingly difficult scientific problems. For those products that successfully make it through development, the regulatory approval bar is higher than ever.
View this whitepaper by clicking the link under the "Download attachments" section below.
Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications, announced the signing of a Distribution Agreement with ATMI, Inc. (NASDAQ: ATMI), a global technology company and a leader in single-use process solutions. Over the last two years, and after several collaborative projects, the relationship between the companies has gained in strategic importance.
Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, today confirmed plans for a state-of–the-art Life Sciences Centre of Excellence at its new Harbourgate site in Portsmouth in the United Kingdom (UK). The Centre of Excellence (COE), which will open in mid 2013, will offer a full suite of capabilities including cell culture, purification, analytical solutions, protein characterization and microbiological tools. This latest COE will complement recently announced Life Sciences Centres in the United States (Westborough, Massachusetts and Menlo Park, California) as well as investments previously announced in China, Singapore and India.
Privately held BIND Therapeutics Inc. – which disclosed its name change from BIND Biosciences Inc. on Tuesday – didn’t let the dust settle after a potential $180.5 million deal with Amgen Inc. in January. This morning, the Cambridge, Mass.-based biotech revealed that Pfizer Inc. sealed an even bigger global collaboration to develop and commercialize multiple Accurins in small molecule targeted therapies.
Finesse Solutions, Inc., a manufacturer of measurement and control solutions for life sciences process applications, announced the launch of its new SmartParts™ family of intelligent transmitters and actuators. SmartParts are the building blocks for Finesse’s next generation of bioreactor controller systems that are intelligent and universal. In this context intelligent and universal indicate that they have plug-and-play capability and can control any size or type of upstream vessel. This reduces complexity and increases efficiency and flexibility for the end user.
Finesse Solutions, Inc., Santa Clara, CA, a manufacturer of measurement and control solutions for life science process applications, announced the release of TruBio® DV version 4.5 bioreactor control software that leverages its new SmartParts™ components. TruBio software can automate a wide variety of bioreactors, ranging from 0.5L bench-scale glass to 2,000L cGMP single-use production vessels. Since its first launch in 2007, TruBio DV continues to be powered by a DeltaV® Controller from Emerson Process Management; TruBio DV version 4.5 is optimized for DeltaV version 11.3.
Recombumin® Alpha used by MAQUET CARDIOPULMONARY in a version of the company’s proprietary BIOLINE Coating
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that one of its leading customers has achieved approval of a medical device in Japan using Recombumin® Alpha - formerly Albucult®, a recombinant human albumin (rAlbumin) product. Recombumin Alpha is used by MAQUET in a version of the company’s proprietary BIOLINE Coating, which has already received regulatory approval and is being used successfully in many countries around the world. This approval represents yet another landmark registration for Novozymes Biopharma’s Recombumin portfolio and the first for a medical device product in Japan.
Ludwigshafen, Germany - Phenex Pharmaceuticals AG (Phenex) today announced it has entered into an agreement with Janssen Biotech, Inc. and its affiliates (Janssen) to jointly discover compounds that target the nuclear hormone receptor RORγT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
Hercules, CA — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products today announced that they have acquired a new cell sorting system from Propel Labs.
Under the terms of agreement, Bio-Rad has acquired an automated, easy-to-use benchtop sorting flow cytometer. The instrument will be offered by Bio-Rad as the S3™ Cell Sorter. First shipments are anticipated in January 2013. Other terms of the agreement were not disclosed.
Want more? Visit...